ProJenX develops Prosetin, a brain-penetrant MAP4K inhibitor therapy currently in clinical trials for Amyotrophic Lateral Sclerosis (ALS). This compound targets endoplasmic reticulum (ER) stress, a common feature across ALS subtypes, to rescue motor neuron loss. The company is also exploring MAP4K inhibition for other neurodegenerative disorders involving ER stress-mediated degeneration.
Funding
$21M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
TAFounders
Product
Problem
Amyotrophic lateral sclerosis (ALS) lacks effective treatments that can readily cross the blood-brain barrier to target motor neuron degeneration. Current therapeutic options fail to adequately address endoplasmic reticulum (ER) stress, a key factor in motor neuron loss across ALS subtypes.
Solution
ProJenX is developing prosetin, a first-in-class, brain-penetrant MAP4 kinase inhibitor designed to treat ALS. Prosetin preferentially reaches the brain to directly target motor neurons and has demonstrated effectiveness in preclinical ALS models. By blocking MAP4K, prosetin aims to rescue ER stress-mediated motor neuron loss, a common feature across ALS subtypes. The company is also exploring the role of MAP4K inhibition in treating other neurodegenerative disorders that trigger ER stress-mediated degeneration of neurons.
Target Audience
The primary target audience is individuals diagnosed with ALS and other neurodegenerative disorders, along with the medical professionals who treat them.
Features
- Brain-penetrant MAP4 kinase inhibitor designed to cross the blood-brain barrier
- Targets endoplasmic reticulum (ER) stress, a common feature across ALS subtypes
- Demonstrated efficacy in preclinical, patient-derived laboratory models of ALS
- Inhibits MAP4K to rescue ER stress-mediated motor neuron loss
- Pipeline development includes novel kinase inhibitors for Parkinson’s disease, Glioblastoma, and Alzheimer’s disease